The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population

被引:48
作者
Chen, XP
Wang, LQ
Zhi, LT
Zhou, GQ
Wang, HJ
Zhang, XM
Hao, BT
Zhu, YP
Cheng, Z
He, FC
机构
[1] Beijing Inst Radiat Med, Dept Genom & Prot, Beijing 100850, Peoples R China
[2] Chinese Natl Human Genome Ctr, Beijing 100850, Peoples R China
[3] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China
[4] Cent S Univ, Sch Pharmaceut Sci, Changsha 410083, Peoples R China
关键词
D O I
10.1016/j.clpt.2005.05.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: This study was designed to better understand genetic variation in the cytochrome P450 (CYP) gene CYP1A2 and its impact on CYP1A2 activity in Chinese subjects. Methods. CYP1A2 genetic polymorphisms were screened by direct sequencing in 27 selected Chinese subjects. Plasma 1,7-dimethylxanthine/caffeine ratios 5 hours after a 100-mg caffeine administration, used as an index of CYP1A2 in vivo activity, were determined in 422 healthy subjects. Five single-nucleotide polymorphism markers, including G-860A (CYP1A2*1C), T-3594G, G-3113A, A-163C (CYP1A2*1F), and C5347T (CYP1A2*1B), were selected and genotyped by either polymerase chain reaction-restriction fragment length polymorphism or direct sequencing. Results. Thirteen polymorphisms and 2 linkage disequilibrium blocks with a boundary around -2467 were identified at this locus. The allele frequency for -3860A, -3594G, -3113A, -163C, and 5347T was 0.21, 0.15, 0.10, 0.36, and 0.14, respectively, in the CYP1A2-phenotyped cohort. A significant difference in CYP1A2 activity was observed among genotypes of polymorphism G-3113A (P = .038), and CYP1A2 activity in subjects carrying the AA genotype was lower than that in those carrying the GA (P = .096) and GG genotypes (P = .036): -0.45 +/- 0.05 (mean +/- SD), -0.32 +/- 0.16, and -0.29 +/- 0.16, respectively. Further analysis based on haplotype pairs found a 1.92-fold variation (95% confidence interval, 1.13-2.71) in mean CYP1A2 activity between haplotype pairs 13 and 15, and the difference was significant (-0.19 +/- 0.15 versus -0.45 +/- 0.05, P = .016). As compared with haplotype pair 10, haplotype pairs 9 and 15 and most haplotype pairs heterozygous for the haplotype with an A allele at -3113, including pairs 5, 8, and 12, also showed significantly lower CYP1A2 activity (P = .015,.048,.008,.024, and .014 for pairs 5, 8, 9, 12, and 15, respectively). In addition, haplotype pairs 5, 9, and 12 also showed significantly lower CYP1A-2 activity than pair 13 (P = .034,.020, and .037 for pairs 5, 9, and 12, respectively). Conclusions: The G-3113A polymorphism is associated with decreased CYP1A2 activity, haplotype pairs 10 and 13 are responsible for high CYP1A2 activity, and haplotype pairs 5, 8, 9, 12, and 15 are responsible for low CYP1A2 activity in Chinese subjects.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 37 条
[1]   Identification of novel polymorphisms in the 5′ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance [J].
Aitchison, KJ ;
Gonzalez, FJ ;
Quattrochi, LC ;
Sapone, A ;
Zhao, JH ;
Zaher, H ;
Elizondo, G ;
Bryant, C ;
Munro, J ;
Collier, DA ;
Makoff, AJ ;
Kerwin, RW .
PHARMACOGENETICS, 2000, 10 (08) :695-704
[2]   Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1 [J].
Aklillu, E ;
Carrillo, JA ;
Makonnen, E ;
Hellman, K ;
Pitarque, M ;
Bertilsson, L ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2003, 64 (03) :659-669
[3]   Identification of a novel splice-site mutation in the CYP1A2 gene [J].
Allorge, D ;
Chevalier, D ;
Lo-Guidice, JM ;
Cauffiez, C ;
Suard, F ;
Baumann, P ;
Eap, CB ;
Broly, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) :341-344
[4]   The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate [J].
Bartoli, A ;
Xiaodong, S ;
Gatti, G ;
Cipolla, G ;
Marchiselli, R ;
Perucca, E .
THERAPEUTIC DRUG MONITORING, 1996, 18 (05) :586-591
[5]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[6]   Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine [J].
Carrillo, JA ;
Christensen, M ;
Ramos, SI ;
Alm, C ;
Dahl, ML ;
Benítez, J ;
Bertilsson, L .
THERAPEUTIC DRUG MONITORING, 2000, 22 (04) :409-417
[7]   Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine [J].
Carrillo, JA ;
Herráiz, AG ;
Ramos, SI ;
Gervasini, G ;
Vizcaíno, S ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (02) :119-127
[8]  
CHUNG I, 1995, MOL PHARMACOL, V47, P677
[9]   Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene [J].
Chung, IJ ;
Bresnick, E .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 338 (02) :220-226
[10]   Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [J].
Drysdale, CM ;
McGraw, DW ;
Stack, CB ;
Stephens, JC ;
Judson, RS ;
Nandabalan, K ;
Arnold, K ;
Ruano, G ;
Liggett, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10483-10488